Last reviewed · How we verify
Lopinavir/ritonavir + nevirapine
This combination inhibits HIV protease (lopinavir/ritonavir) and reverse transcriptase (nevirapine) to suppress viral replication.
This combination inhibits HIV protease (lopinavir/ritonavir) and reverse transcriptase (nevirapine) to suppress viral replication. Used for HIV-1 infection.
At a glance
| Generic name | Lopinavir/ritonavir + nevirapine |
|---|---|
| Sponsor | Amsterdam UMC, location VUmc |
| Drug class | Antiretroviral combination therapy (protease inhibitor + non-nucleoside reverse transcriptase inhibitor) |
| Target | HIV protease; HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Lopinavir and ritonavir are protease inhibitors that block HIV protease, preventing the maturation of infectious viral particles. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks the enzyme responsible for converting HIV RNA into DNA. Together, they target two critical steps in the HIV replication cycle, reducing viral load and slowing disease progression.
Approved indications
- HIV-1 infection
Common side effects
- Nausea
- Diarrhea
- Rash
- Hepatotoxicity
- Lipid abnormalities
- Gastrointestinal disturbance
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission (PHASE1, PHASE2)
- Research on the Psychological Status of Patients With HIV-1 Infection
- Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lopinavir/ritonavir + nevirapine CI brief — competitive landscape report
- Lopinavir/ritonavir + nevirapine updates RSS · CI watch RSS
- Amsterdam UMC, location VUmc portfolio CI